|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Novel System for HIV-1 Vaccine Development |
Description of Invention:
The available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies further include a comprehensive system for immunogen design, comprising in silico design coupled to feedback from X-ray crystallography, antigenic analysis, and immunization.
The described methodology demonstrates how to transplant a given HIV-1 epitope recognized by broadly neutralizing antibodies into an appropriate scaffold, while preserving its structure and antigenicity. Conservation of the three dimensional structure may lead to the generation of antibodies with broadly neutralizing characteristics, similar to the template antibody. Such epitope-transplant scaffolds may serve as valuable diagnostics to identify specific serum reactivity against the target HIV-1 epitopes. The subject scaffolding technology may be applied to any virus for which a broadly neutralizing antibody and its respective epitope has been characterized at the atomic-level.
Applications:
- Immunogens that elicit immune responses to HIV-1
- Efficient development of vaccines against HIV-1
- Screening tool to isolate antibodies with activities similar to identified template antibody
Inventors:
Peter D Kwong (NIAID)
Patent Status:
HHS, Reference No. E-218-2004/0
US, , Patent No. 8147840, Issued 03 Apr 2012 (claiming priority to 14 May 2004), entitled "HIV Vaccine Immunogens and Immunization Strategies to Elicit Broadly-Neutralizing Anti-HIV-1 Antibodies Against the Membrane Proximal of HIV gp41"
US, , Patent No. 8,044,185, Issued 25 Oct 2011 (claiming priority to 06 Sep 2005), entitled "Conformationally Stabilized HIV Envelope Immunogens and Triggering HIV-1 Envelope to Reveal Cryptic V3-Loop Epitopes"
PCT, Application No. PCT/US2005/016633 filed 13 May 2005
PCT, Application No. PCT/US2006/034681 filed 06 Sep 2006
PCT, Application No. PCT/US2006/034882 filed 06 Sep 2006
US, , Patent No. 8,268,323, Issued 18 Sep 2012
US, Application No. 13/585,700 filed 14 Aug 2012
Relevant Publication:
- G Ofek, W Schief, J Guenaga, et al. Epitope-transplant scaffolds: automated design, structural analysis, and antigenic characteristics. Manuscript in preparation (2007).
- T Zhou, L Xu, B Dey, AJ Hessell, DV Ryk, SH Xiang, X Yang, MY Zhang, MB Zwick, J Arthos, DR Burton, DS Dimitrov, J Sodroski, R Wyatt, GJ Nabel, PD Kwong. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007 Feb 15;445(7129):732-737. [PubMed abs]
- DC Douek, PD Kwong, GJ Nabel. The rational design of an AIDS vaccine. Cell. 2006 Feb 24;124(4):677-681. [PubMed abs]
- G Ofek, M Tang, A Sambor, H Katinger, JR Mascola, R Wyatt, PD Kwong. Structure and mechanistic analysis of the anti-HIV-1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004 Oct;78(19):10724-10737. [PubMed abs]
Licensing Status:
Available for licensing.
For Licensing Information Please Contact:
Cristina Thalhammer-Reyero Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Room 33,
Rockville, MD 20852
United States
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507
Fax: 301-402-0220
Ref No: 1506
Updated: 03/2007
|
|
|
|
| |
|
|
|
|